Wedelolactone 通过直接抑制 IKK 复合物抑制 lps 诱导的caspase-11表达。Wedelolactone 抑制5-Lox,其IC50值为 2.5 μM。Wedelolactone 通过下调 PKCε 诱导的 caspase 依赖的前列腺癌细胞凋亡,而不抑制 Akt。Wedelolactone 可从鳢肠中提取,可用于癌症的研究。
生物活性 | Wedelolactone suppresses LPS-inducedcaspase-11expression by directly inhibits theIKKComplex. Wedelolactone also inhibits5-lipoxygenase(5-Lox) with anIC50of 2.5 μM. Wedelolactone induces caspase-dependentapoptosisin prostatecancercells via downregulation ofPKCεwithout inhibitingAkt. Wedelolactone can extract from Eclipta alba, and it can be used for the research ofcancer[1][2][3]. |
IC50& Target[1][2][3] | Caspase-11 | 5-LOX 2.5 μM (IC50) | Apoptosis |
|
体外研究 (In Vitro) | Wedelolactone (0-5 μg/mL; 0-21 d) enhances bone marrow mesenchymal stem cells (BMSC) differentiation towards osteoblasts[3].Wedelolactone (0-6 μg/mL; 0-9 d) inhibits GSK3β activity and increases β-catenin and runx2 nuclear accumulation in BMSC, and inhibits the effect of RANKL[3].Wedelolactone (0-5 μg/ml; 60 min) inhibits GSK3β activity and proves GSK3β is the target of wedelolactone[3].Wedelolactone (0-5 μg/ml; 6 d) inhibits c-src, c-fos and cathepsin k expression level[3].
Cell Differentiation Assay[3] Cell Line: | Mouse BMSC | Concentration: | 0-5 μg/mL | Incubation Time: | 0, 6, 9, 12 and 21 days | Result: | Increased Mouse BMSC into osteoblastic cells and dose-dependently increased the activity of alkaline phosphatase at incubation for 9 days. |
Western Blot Analysis[3] Cell Line: | Mouse BMSC and RAW264.7 cells | Concentration: | 0-5 μg/mL | Incubation Time: | 0-9 days | Result: | Decreased GSK3β expression level and up-regulated GSK3β phosphorylation, nuclear accumulation of β-catenin and runx2 in BMSC. Inhibited RANKL-induced phosphorylation of NF-κB/p65 and the expression level of c-fos and c-Src. |
Cell Viability Assay[3] Cell Line: | Mouse BMSC | Concentration: | 0.1, 1.25, 2.5, 5 μg/ml | Incubation Time: | 60 min | Result: | Inhibited GSK3β activity with an IC50of 21.7 μM weeker than staurosporin which is a GSK3β inhibitor and proved GSK3β is a target. |
RT-PCR[3] Cell Line: | RAW264.7 cells | Concentration: | 0, 0.6, 1.25, 2.5 and 5 μg/mL | Incubation Time: | 6 days | Result: | Inhibited the expression of osteoclast differentiation related marker genes c-src, c-fos and cathepsin in RAW264.7 cells. |
|
体内研究 (In Vivo) | Wedelolactone (10 mg/kg; i.p. every 2 days for 4 weeks) decreases bone volumn and trabecular number at the femur after ovarietomy, and prevents the VOX-induced bone loss[3].
Animal Model: | Ovariectomized 9-week-old mice[3] | Dosage: | 10 mg/kg | Administration: | Intraperitoneal injection; 10 mg/kg every 2 days; for 4 weeks | Result: | Inhibited osteoclast activity and stimulated osteoblast differentiation to achieved osteoprotective effect. |
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
中文名称 | |
结构分类 | |
来源 | - Plants
- Compositae
- Eclipta prostrata(Linn.) Linn.
|
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Powder | -20°C | 3 years | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
溶解性数据 | In Vitro: DMSO : 125 mg/mL(397.77 mM;Need ultrasonic) 配制储备液 1 mM | 3.1822 mL | 15.9109 mL | 31.8218 mL | 5 mM | 0.6364 mL | 3.1822 mL | 6.3644 mL | 10 mM | 0.3182 mL | 1.5911 mL | 3.1822 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.08 mg/mL (6.62 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (6.62 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 2.08 mg/mL (6.62 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (6.62 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|